Cite
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
MLA
Lidia Giraudo, et al. “CSPG4 CAR-Redirected Cytokine Induced Killer Lymphocytes (CIK) as Effective Cellular Immunotherapy for HLA Class I Defective Melanoma.” Journal of Experimental & Clinical Cancer Research, vol. 42, no. 1, Nov. 2023, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s13046-023-02884-x.
APA
Lidia Giraudo, Giulia Cattaneo, Loretta Gammaitoni, Ilenia Iaia, Chiara Donini, Annamaria Massa, Maria Laura Centomo, Marco Basiricò, Elisa Vigna, Alberto Pisacane, Franco Picciotto, Enrico Berrino, Caterina Marchiò, Alessandra Merlini, Luca Paruzzo, Stefano Poletto, Daniela Caravelli, Andrea Michela Biolato, Valentina Bortolot, … Dario Sangiolo. (2023). CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma. Journal of Experimental & Clinical Cancer Research, 42(1), 1–13. https://doi.org/10.1186/s13046-023-02884-x
Chicago
Lidia Giraudo, Giulia Cattaneo, Loretta Gammaitoni, Ilenia Iaia, Chiara Donini, Annamaria Massa, Maria Laura Centomo, et al. 2023. “CSPG4 CAR-Redirected Cytokine Induced Killer Lymphocytes (CIK) as Effective Cellular Immunotherapy for HLA Class I Defective Melanoma.” Journal of Experimental & Clinical Cancer Research 42 (1): 1–13. doi:10.1186/s13046-023-02884-x.